Lundbeck
Business & Industry
- Bayer and Puhe BioPharma enter into global license agreement for clinical phase I PRMT5 inhibitor
- AstraZeneca enters license agreement with Alteogen
- Roche enters into an exclusive collaboration & licensing agreement with Zealand Pharma
- Bayer and Hurdle announce breakthrough in aging research
- GSK completes acquisition of IDRx, Inc.
Research & Development
- Preclinical study: after heart attack, a boost in anti-inflammatory cells promoted healing
- Enzyme engineering opens door to novel therapies for Parkinson's, cancers and other hard-to-target protein diseases
- New tool to boost cancer immunotherapy effects
- Scientists identify potential new genetic target for sickle cell disease treatment
- Keeping fit and building muscle could increase survival rates in cancer patients
- Continued medication important for heart failure patients
- Newly identified bacterial protein helps design cancer drug delivery system
Conferences & Events
- New insights into T and B cells offer hope for autoimmune disease sufferers
- SAE Media Group proudly presents the 4th Annual AI in Drug Discovery Conference
- SAE Media Group's 6th annual 3D Cell Culture Conference
- CPHI Frankfurt returns to pre-pandemic strength as pharma industry booms again
- 14th Annual RNA Therapeutics: Investigating the next generation of genetic medicine through RNA based therapies
- CPHI Excellence in Pharma Award Winners 2022
- CPHI Frankfurt Report predicts huge funding overhang to drive contract services growth
Regulatory Affairs
- FDA approves first gene therapy for treatment of aromatic L-amino acid decarboxylase deficiency
- FDA approves new treatment for hemophilia A or B
- FDA approves nasal spray influenza vaccine for self- or caregiver-administration
- FDA approves first nasal spray for treatment of anaphylaxis
- FDA approves nonsteroidal treatment for Duchenne muscular dystrophy